Veracyte Inc
$ 46.41
0.30%
11 Aug - close price
- Market Cap 3,730,934,000 USD
- Current Price $ 46.41
- High / Low $ 46.67 / 45.72
- Stock P/E 33.15
- Book Value 16.50
- EPS 1.40
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.09 %
- 52 Week High 60.91
- 52 Week Low 28.25
About
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$57.82
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-05 | 2026-02-25 | 2025-11-04 | 2025-08-06 | 2025-05-07 | 2025-02-24 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 |
| Reported EPS | 0.37 | 0.52 | 0.53 | 0.51 | 0.44 | 0.31 | 0.36 | 0.33 | 0.3 | 0.04 | -0.39 | -0.41 |
| Estimated EPS | 0.29 | 0.33 | 0.39 | 0.32 | 0.3 | 0.2 | 0.2571 | 0.17 | -0.01 | -0.1 | -0.09 | -0.13 |
| Surprise | 0.08 | 0.19 | 0.14 | 0.19 | 0.14 | 0.11 | 0.1029 | 0.16 | 0.31 | 0.14 | -0.3 | -0.28 |
| Surprise Percentage | 27.5862% | 57.5758% | 35.8974% | 59.375% | 46.6667% | 55% | 40.0233% | 94.1176% | 3100% | 140% | -333.3333% | -215.3846% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VCYT
2026-08-11 15:10:09
Veracyte (VCYT) outlined a strategy for growth balanced with disciplined spending at Canaccord Genuity’s 46th Annual Growth Conference. The company raised its full-year 2024 revenue guidance to $600 million after strong Q2 results, achieving over 29% adjusted EBITDA margin and over $40 million in cash generation. While Decipher volume growth slowed due to a guideline change affecting low-risk segments, Afirma continued to benefit from a sequencer transition, and new products Prosigna and TrueMRD were launched, though not yet materially contributing to revenue.
2026-08-07 22:10:18
Janus Henderson Group PLC reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 31% in the first quarter, selling 84,255 shares but still retaining 187,368 shares valued at approximately $6 million. Despite this sale, analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $54.33. Other institutional investors like Jane Street and UBS Asset Management increased their positions in Veracyte, while the company reported strong quarterly earnings of $0.54 per share, beating estimates.
2026-08-07 18:10:09
Royal Bank of Canada increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 66.4% in the first quarter, acquiring an additional 228,720 shares, bringing its total to 573,096 shares valued at approximately $18.46 million. This move is part of a broader trend of institutional investors boosting their positions in Veracyte, while company insiders have sold shares worth about $9.68 million over the past 90 days. Veracyte also reported strong quarterly earnings, beating analyst expectations with $0.54 EPS and $150.32 million in revenue, a 15.5% year-over-year increase, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $54.33.
2026-08-06 14:45:24
Veracyte Inc (VCYT) has an earnings forecast score of 8.46, ranking 126th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $48.00, with a consensus "Buy" rating based on 13 analysts. The company's expected revenue for the next quarter is $147.64 million, and its previous quarter's EPS was $0.36, exceeding the market expectation of $0.32.
2026-08-05 22:40:24
Veracyte, Inc. exceeded analyst expectations for its quarterly results, with revenues hitting US$150m and statutory EPS at US$0.31, 19% above forecasts. Following these positive results, analysts have slightly increased their earnings per share outlook for 2026, though the consensus revenue estimates remain largely unchanged. Despite the improved earnings potential, the consensus price target for Veracyte held steady at US$57.82, and the company's projected revenue growth is expected to be slower than the wider industry.
2026-08-05 12:50:35
Veracyte, Inc. exceeded analyst expectations for its recent quarterly results, with revenues reaching US$150 million and statutory EPS at US$0.31, both higher than forecasts. Following these positive results, analysts have modestly increased their revenue and earnings per share predictions for 2026, though the consensus price target remains unchanged at US$57.82. The company's revenue growth is expected to slow compared to historical rates and the wider industry.
